Literature DB >> 15094603

[HER2 gene amplification assay: is CISH an alternative to FISH?].

Yves Denoux1, Laurent Arnould, Maryse Fiche, B Lannes, Jérôme Couturier, Anne Vincent-Salomon, Frédérique Penault-Llorca, M Antoine, A Balaton, M C Baranzelli, V Becette, J P Bellocq, F Bibeau, F Ettore, V Fridman, J P Gnassia, J Jacquemier, G MacGrogan, M C Mathieu, C Migeon, C Rigaud, P Roger, B Sigal-Zafrani, J Simony-Lafontaine, M Trassard, I Treilleux, V Verriele, J J Voigt.   

Abstract

The HER2 proto-oncogene encodes a transmembrane protein, which is considered to function as a growth factor receptor. Overexpression of this protein found by immunohistochemistry in about 20% of infiltrating breast carcinomas, has a predictive value of response to treatment by trastuzumab, an anti-HER2 humanized monoclonal antibody. Search for HER2 gene amplification is necessary to adapt the immunohistochemical technique quality and also in the cases of delicate analysis or weak overexpression. It is usually carried out by Fluorescence In Situ Hybridization (FISH). A more recent hybridization technique, named CISH because of its chromogenic revelation is an alternative method, which gives highly correlated results with FISH. We present details of this technique, which may be more familiar for the pathologists than FISH, because reading analysis is similar to that of immunohistochemical staining.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15094603

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  2 in total

1.  Trastuzumab in the management of early and advanced stage breast cancer.

Authors:  Rupert Bartsch; Catharina Wenzel; Guenther G Steger
Journal:  Biologics       Date:  2007-03

2.  SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Authors:  Jocelyne Jacquemier; Frédérique Spyratos; Benjamin Esterni; Marie-Joëlle Mozziconacci; Martine Antoine; Laurent Arnould; Sarab Lizard; Philippe Bertheau; Jacqueline Lehmann-Che; Cécile Blanc Fournier; Sophie Krieger; Frédéric Bibeau; Pierre-Jean Lamy; Marie Pierre Chenard; Michèle Legrain; Jean-Marc Guinebretière; Delphine Loussouarn; Gaëtan Macgrogan; Isabelle Hostein; Marie Christine Mathieu; Ludovic Lacroix; Alexander Valent; Yves Marie Robin; Françoise Revillion; Magali Lacroix Triki; Aline Seaume; Anne Vincent Salomon; Patricia de Cremoux; Geneviève Portefaix; Luc Xerri; Sophie Vacher; Ivan Bièche; Frédérique Penault-Llorca
Journal:  BMC Cancer       Date:  2013-07-22       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.